Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus thermophilus TCI633 is a probiotic bacterial strain originally isolated from human breast milk and developed by TCI Co., Ltd. The strain is characterized by its ability to colonize the gastrointestinal tract and endogenously produce hyaluronic acid (HA). This mechanism is intended to provide systemic benefits, particularly in the management of musculoskeletal conditions. Clinical and preclinical studies have investigated TCI633 for the treatment of knee osteoarthritis (KOA), where it has demonstrated potential in reducing synovial tissue inflammation, protecting cartilage, and improving joint function as measured by WOMAC scores and biomarkers like sCTX-II and sCRP. Beyond joint health, the strain is explored for its anti-aging properties and potential to improve skin hydration and collagen synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on streptococcus thermophilus TCI633.